Insight Surgery completes $2.5m Series A led by Nodenza Venture Partners for US expansion of personalized surgery
Houston, Texas, May 14 2025, Insight Surgery (‘Insight’), a pioneering personalized surgery technology company, has completed a $2.5m Series A equity investment led by Nodenza Venture Partners (‘Nodenza’).
This investment follows the granting of FDA 510(k) clearance for the company’s surgical guides for orthopedic and orthopedic-oncology surgery and will be used to further accelerate their recent growth in the US market. Their planned expansion will provide surgeons with rapid access to sophisticated tools that improve patient outcomes, reduce risk and expedite recovery.
The new frontier of surgical planning
Insight’s proprietary digital platform, EmbedMed, digitizes the surgical planning process and allows the rapid design and manufacture of the patient-specific guides for orthopaedic surgery
Functions include the processing of patient scan data and as a pre-operative software tool for simulating and evaluating surgical planning options. The output files from the system can be provided digitally, or as physical models and Surgical Guides. The advanced nature of the platform enables Surgical Guides to be provided to surgeons in 10 working days from Insight’s ISO 13485-certified and FDA-registered facilities in the US.
World leading medical technology, manufactured in the US
Insight Surgery recently launched their US business with the opening of a cleanroom manufacturing facility at the Texas Medical Centre (TMC), Houston. They have since gained considerable market traction, entering into a strategic partnership with Ricoh USA and partnering with world-leading surgeons at several major hospitals across the US, including the Hospital for Special Surgery in New York, University Hospitals of Chicago, University of Florida Health, and UAB in Birmingham Alabama.
Their Series A raise, and the support of the Nodenza team, will unlock expansion opportunities for Insight Surgery across the US, including the opening of two new manufacturing facilities at East and West-coast hospital sites. The company has plans to double headcount in the US in the coming months.
Henry Pinchbeck, Chief Executive Officer at Insight Surgery, said:
“Our mission is to make advanced surgical planning tools accessible and scalable across the US healthcare system. This investment allows us to accelerate our plan to enable every orthopedic surgeon in the US to have easy access to Personalized Surgical devices within surgically meaningful timelines.
“We’re excited to build on the momentum we’ve already seen with leading clinicians.
“We’re not just focused on improving surgical precision – we’re focused on doing it in a way that makes financial sense for healthcare systems. By reducing operating time, streamlining workflows, and lowering complication and readmission rates, our technology can help hospitals drive down costs while delivering better care. This investment allows us to scale that impact nationwide.”
Ross Morton, Managing Partner at Nodenza Venture Partners, said:
“Insight Surgery is exactly the kind of company we look to back. Disruptive tech, with clear benefits to patients being delivered now not tomorrow, and – with the right funding in place – the potential to be the leader in the personalized surgery market. Their platform addresses a real need in orthopedic surgery by enabling better outcomes via bespoke products, which resonates with both surgeons and health systems looking to meet patient demand in personalized surgery. We believe Insight, with the support that the Nodenza team can provide, is well-positioned to scale rapidly across the US.”
Dr Adam Levin, leading Musculoskeletal Oncology surgeon, commented:
“Insight’s technology makes it possible for me and my colleagues to operate with greater precision and speed, which directly improves outcomes for patients and reduces the likelihood of costly complications. For hospitals and providers, this means fewer revisions, shorter operative times, and faster recoveries. It’s a rare example of a surgical innovation that’s both clinically and economically compelling.”
